• About us
• Contact

Advertisement

Organisation › Details

Novartis Venture Fund (NVF)

The Novartis Venture Funds, established in 1996 currently manage over $750 million in committed capital. NVF invests in companies which have the potential to change a core therapeutic field or explore new business areas that will be critical to patient care. With eight investment professionals located in Basel, Switzerland and Cambridge, MA, the team has extensive experience in pharmaceutical R&D, medical devices, diagnostics and venture capital. *

 

	Start	1996-01-01 established
	Group	Novartis (Group)
	Industry	venture capital
	Industry 2	LIFE SCIENCES
	Person	Murray, Campbell (Novartis 201203 Managing Director of Novartis Venture Fund)
	Person 2	Gros, Florent (Earlybird 202206 formerly Novartis 201107 Managing Director of Novartis Venture Fund)
	Region	Basel BS
	Country	Switzerland
	Street	Novartis International AG, P.O. Box
	City	4002 Basel
		Address record changed: 2020-12-02
Basic data	Employees	A: 1 to 10 (2015-01-29)
	Currency	USD
	Annual sales	750,000,000 (capital, committed 2015-01-29)
		* Document for »About Section«:
		Record changed: 2023-06-22

Advertisement

More documents for Novartis (Group)

• [1] Legend Biotech Corporation. (11/13/23). "Press Release: Legend Biotech Announces Exclusive, Global License Agreement for Certain CAR-T Therapies Targeting DLL3". Somerset, NJ....
• [2] Sandoz Group AG. (10/4/23). "Press Release: Sandoz Enters New Era as Standalone Global Leader and European Champion in Generic and Biosimilar Medicines". Basel....
• [3] BeiGene, Ltd.. (9/19/23). "Press Release: BeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody Tevimbra (tislelizumab)". Basel & Beijing & Cambridge, MA....
• [4] Novartis AG. (9/11/23). "Press Release: Sandoz Announces Exclusive Deal to Commercialize Biosimilar Ustekinumab". Basel....
• [5] Intellegens Ltd.. (8/30/23). "Press Release: Intellegens and CPI Awarded £1.6m Innovate UK Grant to Advance Manufacture of Oligonucleotide Therapeutics with Machine Learning". Cambridge....
• [6] Novartis AG. (7/20/23). "Press Release: Sandoz Announces Plans to Build a Biosimilar Technical Development Center in Slovenia to Support Future Growth of Biosimilar Pipeline". Basel....
• [7] BioGeneration Ventures B.V.. (7/19/23). "Press Release: Dr. Markus Kalousek and Dr. Andrew Lightfoot Join BGV as Venture Partners". Amsterdam....
• [8] Novartis AG. (7/17/23). "Press Release: Novartis Builds on Neuroscience Pipeline and xRNA Platform Capabilities with Acquisition of DTx Pharma". Basel....
• [9] Galapagos N.V.. (6/12/23). "Pressemitteilung: Galapagos Appoints Dr. Susanne Schaffert as Non-executive Independent Director to Its Board". Mechelen....
• [10] Novartis AG. (6/12/23). "Pressemitteilung: Novartis Bolsters Innovative Medicines Strategy and Renal Pipeline with Agreement to Acquire Chinook Therapeutics for USD 3.2bn Upfront (USD 40 / Share)". Basel....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2023. Made in Germany.